We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




NIH’s Observational Medical Outcomes Partnership Seeks Public Feedback on Research Priorities

By LabMedica International staff writers
Posted on 17 Sep 2012
The Foundation for the US National Institutes of Health (Bethesda, MD, USA) managed Observational Medical Outcomes Partnership (OMOP) is seeking public feedback on proposed research priorities and tasks. More...


OMOP was formed in 2008 to conduct methodologic research to inform the suitable use of observational healthcare data for studying the effects of medical products. OMOP has generated empirical evidence about the performance of observational analysis methods to identify real risks of medical products and discriminate from false findings. The basic goal of this research is to develop and evaluate standardized algorithms that can effectively distinguish positive from negative controls, and to understand how an estimated effect from an observational study relates to the true relationship between medical product exposure and adverse events.

As part of its research, OMOP has developed tools and capabilities for transforming, characterizing, and examining disparate data sources across the healthcare delivery spectrum, and has established a shared resource to enable collaborative research. OMOP’s research continues to reiterate the idea that advancing the science of observational research requires an empirical and reproducible approach to methodology and its systematic application.

To continue the effort, the OMOP executive board proposed a series of priorities, infrastructure tasks, and research tasks to guide the development of OMOP’s research agenda for 2013-2016.

The OMOP executive board is seeking comment on the adequacy and completeness of the research priorities and tasks. “Receiving public feedback regarding OMOP’s work is vital to our success,” said OMOP executive board member, Ronald Krall, MD. “We want to make sure we hear every idea about how to use healthcare data to improve the safety and effectiveness of medical products.”

The proposed research priorities and tasks are found on the OMOP website with instructions on how to provide feedback. Comments can be given through September 15, 2012.

Established by the United States Congress to support the mission of the NIH--improving health through scientific discovery in the search for cure--the Foundation for the NIH is a leader in identifying and addressing complex scientific and health issues.

Related Links:
Foundation for the US National Institutes of Health
Observational Medical Outcomes Partnership


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
All-in-One Molecular System
AIO M160
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.